Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.39 |
| ▸ | PDE4A | P27815 | 5/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21491449 | 1.00 | KMT2A (0.43) | KMT2AMEN1MAPTPDE4DPDE4A | |
| SCHEMBL21491303 | 0.89 | CA12 (0.44) | MAPTPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL24313200 | 0.89 | CCNC (0.40) | KMT2AMEN1MAPTPDE4DPDE4A | |
| Hydrochloric Acid SCHEMBL21491110 | 0.88 | CA12 (0.43) | MAPTPDE4DPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL29456315 | 0.88 | CA12 (0.43) | MAPTPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL21491317 | 0.86 | ALDH1A1 (0.41) | KMT2AMEN1MAPTALOX15ALDH1A1 | |
| SCHEMBL21491473 | 0.84 | ALDH1A1 (0.39) | KMT2AMEN1MAPTALOX15ALDH1A1 | |
| SCHEMBL31472369 | 0.73 | ALOX15 (0.39) | KMT2AMEN1MAPTPDE4DPDE4A | |
| SCHEMBL21491219 | 0.73 | ALOX15 (0.39) | KMT2AMEN1MAPTPDE4DPDE4A | |
| SCHEMBL31472393 | 0.73 | ALOX15 (0.39) | KMT2AMEN1MAPTPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| EP-4043460-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2024-06-05 | — | — | EP | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-11440907-B1 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| EP-4043460-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | KMT2A 2819/4885MEN1 1423/4885MAPT 3920/4885 |
| US-11440907-B1 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | KMT2A 2819/4885MEN1 1423/4885MAPT 3920/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | KMT2A 2819/4885MEN1 1423/4885MAPT 3920/4885 |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | KMT2A 2819/4885MEN1 1423/4885MAPT 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.